Cordlife Group Limited announced its interim financial results for the nine months ended September 2025, detailing operational instability and continuous regulatory scrutiny. While the Group reported increased revenue and a reduced net loss, profound uncertainty remains regarding its core business in Singapore. Authorities identified areas of non-compliance, leading to an intended suspension of the critical cord blood banking service licence and requiring further independent review of key storage facilities. The company is focused on operational stability, cooperation with regulators, and rebuilding stakeholder trust.

• Regulatory scrutiny has heightened, with the Director-General of Health intending to suspend the Company's cord blood banking licence for a full year due to identified non-compliance issues

• New testing results have concluded that samples from certain units previously assessed as low-risk failed to meet viability criteria, necessitating a full investigation into those remaining storage tanks

• The Group projects a material decline in new customer sign-ups and disruption to revenue recognition in its home market, although stable overseas operations are expected to continue